Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia
CLOPI-SNAP
Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)
2 other identifiers
interventional
230
1 country
20
Brief Summary
The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Jun 2026
Typical duration for phase_2
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 27, 2026
CompletedFirst Posted
Study publicly available on registry
February 3, 2026
CompletedStudy Start
First participant enrolled
June 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2030
Study Completion
Last participant's last visit for all outcomes
June 1, 2030
February 5, 2026
February 1, 2026
4 years
January 27, 2026
February 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Desirability of Outcome Ranking (DOOR)
Desirability of Outcome Ranking is an ordinal scale that classifies each patient's overall clinical outcome from 1 to 5, integrating survival, clinical response, and serious adverse events. DOOR 1 represents the most favorable outcome (alive with clinical cure or improvement and no serious adverse events); DOOR 2, clinical cure or improvement with serious adverse events; DOOR 3, alive with clinical failure and no serious adverse events; DOOR 4, clinical failure with serious adverse events; and DOOR 5, death, representing the least desirable outcome. Lower numerical values indicate more favorable overall clinical outcomes.
At day 90 from day 0.
Secondary Outcomes (4)
Mortality
At day 14 and day 28 from day of assignment of study drug (day 0)
Length of stay of inpatient hospitalisation
At day 90 from day 0.
Microbiological treatment failure
At day 14 and day 90 from day of assignment of study drug (day 0)
New foci of infection
At day 14 and day 90 from day of assignment of study drug (day 0)
Other Outcomes (1)
Major bleeding
At day 90 from day 0.
Study Arms (2)
Oral clopidogrel
EXPERIMENTALOral clopidogrel 75 mg pills; 300 mg from domain reveal (day 1 of treatment), followed by 75 mg daily until day 5 of treatment inclusive (4 additional calendar days) added to different concurrent antibiotic options currently approved for SAB
No antiplatelet treatment
OTHERPatients receive different concurrent antibiotic options currently approved for SAB
Interventions
Oral clopidogrel 75 mg pills; 300 mg from domain reveal (day 1 of treatment), followed by 75 mg daily until day 5 of treatment inclusive (4 additional calendar days)
Different concurrent antibiotic options currently approved for SAB
Eligibility Criteria
You may qualify if:
- To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria:
- Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.
- Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.
- Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.
You may not qualify if:
- General Medical and Safety Factors:
- Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).
- Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).
- Pregnancy: Pregnant or breastfeeding women.
- High Risk of Bleeding or Hematologic Disorders:
- Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.
- Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment.
- Coagulation parameters: Platelet count \<50,000/mm³ or known coagulation disorders.
- Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted).
- Specific Diagnoses and Clinical Criteria:
- Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Hospital General Universitario de Alicante
Alicante, Spain
H.U. Clinic
Barcelona, Spain
H.U. Mutua Terrassa
Barcelona, Spain
Hospital del Mar
Barcelona, Spain
Hospital Universitario Bellvitge
Barcelona, Spain
Hospital Universitario de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
H.U. Reina Sofía
Córdoba, Spain
Hospital Universitario San Cecilio
Granada, Spain
H.U. Jerez de la Frontera
Jerez de la Frontera, Spain
Hospital Universitario La paz
Madrid, Spain
Hospital Universitario La Princesa
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Spain
Hospital Virgen Macarena
Seville, 41008, Spain
H.U. Virgen del Rocío
Seville, Spain
Hospital Universitario Virgen de Valme
Seville, Spain
Hospital Universitario Marqués de Valdecilla
Valdecilla, Spain
Hospital Universitario Álvaro Cunqueiro
Vigo, Spain
Hospital Universitario Lozano Blesa
Zaragoza, Spain
Related Publications (5)
Campbell AJ, Anpalagan K, Best EJ, Britton PN, Gwee A, Hatcher J, Manley BJ, Marsh J, Webb RH, Davis JS, Mahar RK, McGlothlin A, McMullan B, Meyer M, Mora J, Murthy S, Nourse C, Papenburg J, Schwartz KL, Scheuerman O, Snelling T, Strunk T, Stark M, Voss L, Tong SYC, Bowen AC; Staphylococcus aureus Network Adaptive Platform Paediatric and Youth (SNAP-PY) working groupSNAP Global Trial Steering Committee. Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials. JAMA Pediatr. 2024 Oct 1;178(10):1066-1071. doi: 10.1001/jamapediatrics.2024.2697.
PMID: 39158898BACKGROUNDMahar RK, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, Cheng MP, Daneman N, Goodman AL, Lee TC, Lewis RJ, Lumley T, McLean ARD, McQuilten Z, Mora J, Paterson DL, Price DJ, Roberts J, Snelling T, Tverring J, Webb SA, Yahav D, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8.
PMID: 39934879BACKGROUNDBoyles T, Bowen AC, Chomba R, Nel J, Davis JS, Tong SYC. Inclusion of a low- and middle-income country site in the Staphylococcus aureus Network Adaptive Platform trial: experiences from Johannesburg. Clin Microbiol Infect. 2025 Dec;31(12):1948-1950. doi: 10.1016/j.cmi.2025.06.032. Epub 2025 Jul 4. No abstract available.
PMID: 40618922BACKGROUNDWalls G, McGrath L, Herdman MT, Campbell AJ, Cheng MP, Marks M, Oever JT, Sahng E, Yahav D, Tong SYC, Goodman AL, Lim AG, Bloomfield M; Staphylococcus aureus Network Adaptive Platform Trial Early Oral Switch Domain Specific Working Group. Patient-reported perceptions, experiences and preferences around intravenous and oral antibiotics for the treatment of Staphylococcus aureus bacteremia: a descriptive qualitative study. Clin Infect Dis. 2025 Sep 24:ciaf522. doi: 10.1093/cid/ciaf522. Online ahead of print.
PMID: 40988120BACKGROUNDde Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL; SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee; SNAP Trial Group. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2024 Oct 15;79(4):871-887. doi: 10.1093/cid/ciad666.
PMID: 37921609BACKGROUND
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jesús Rodriguez Baños, PhD
Hospital Universitario Virgen Macarena
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 27, 2026
First Posted
February 3, 2026
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
June 1, 2030
Study Completion (Estimated)
June 1, 2030
Last Updated
February 5, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
The information will be made available upon completion of the study. During the study period and data preparation phase, the information will be under the custody and responsibility of the research team.